Analysis of progression after elective distal ureterectomy and effects of salvage radical nephroureterectomy in patients with distal ureteral urothelial carcinoma

Sci Rep. 2024 Feb 12;14(1):3497. doi: 10.1038/s41598-024-54232-4.

Abstract

We compared the progression patterns after radical nephroureterectomy (RNU) and elective distal ureterectomy (DU) in patients with urothelial carcinoma of the distal ureter. Between Jan 2011 and Dec 2020, 127 patients who underwent RNU and 46 who underwent elective DU for distal ureteral cancer were enrolled in this study. The patterns of progression and upper tract recurrence were compared between the two groups. Progression was defined as a local recurrence and/or distant metastasis after surgery. Upper tract recurrence and subsequent treatment in patients with DU were analyzed. Progression occurred in 35 (27.6%) and 10 (21.7%) patients in the RNU and DU groups, respectively. The progression pattern was not significantly different (p = 0.441), and the most common progression site was the lymph nodes in both groups. Multivariate logistic regression analysis revealed that pT2 stage, concomitant lymphovascular invasion, and nodal stage were significant predictors of disease progression. Upper tract recurrence was observed in nine (19.6%) patients with DU, and six (66.7%) patients had a prior history of bladder tumor. All patients with upper tract recurrence after DU were managed with salvage RNU. Elective DU with or without salvage treatment was not a risk factor for disease progression (p = 0.736), overall survival (p = 0.457), cancer-specific survival (p = 0.169), or intravesical recurrence-free survival (p = 0.921). In terms of progression patterns and oncological outcomes, there was no difference between patients who underwent RNU and elective DU with/without salvage treatment. Elective DU should be considered as a therapeutic option for distal ureter tumor.

Keywords: Distal ureter; Distal ureterectomy; Progression; Radical nephroureterectomy; Therapeutic outcome; Urothelial carcinoma.

MeSH terms

  • Carcinoma, Transitional Cell* / pathology
  • Disease Progression
  • Humans
  • Kidney Neoplasms* / pathology
  • Neoplasm Recurrence, Local / surgery
  • Nephrectomy
  • Nephroureterectomy
  • Retrospective Studies
  • Ureter* / pathology
  • Ureter* / surgery
  • Ureteral Neoplasms*
  • Urinary Bladder Neoplasms* / surgery